Article Information
History
- July 13, 2020.
Article Versions
- Version 1 (July 10, 2020 - 16:09).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Douglas Ferreira Sales-Medina1,
- Ludmila Rodrigues Pinto Ferreira2,
- Lavínia M. D. Romera1,
- Karolina Ribeiro Gonçalves1,
- Rafael V. C. Guido3,
- Gilles Courtemanche4,
- Marcos S. Buckeridge5,
- Édison L. Durigon1,
- Carolina B. Moraes6 and
- Lucio H. Freitas-Junior1,*
- 1Department of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 1374, Sao Paulo-SP 05508-900, Brazil
- 2RNA Systems Biology Laboratory (RSBL), Post-Graduate Program in Cell Biology, Institute of Biological Sciences, Federal University of Minas Gerais & INCT-Vacinas, Av. Antônio Carlos, 6627, Belo Horizonte-MG 31270910, Brazil
- 3São Carlos Institute of Physics, University of Sao Paulo, Avenida João Dagnone, 1100, São Carlos, SP 13563-120, Brasil São Carlos, Brazil
- 4Bioaster, 28, rue du Docteur Roux, 75015 Paris, France
- 5Department of Botany, Institute of Biological Sciences, University of Sao Paulo, Rua do Matão, 277, Sao Paulo-SP 05508-900, Brazil
- 6Department of Pharmaceutical Sciences, Federal University of Sao Paulo, Rua São Nicolau, 210, Diadema – SP 09913-030, Brazil
- ↵*Corresponding author: luciofreitasjunior{at}gmail.com
Posted July 13, 2020.
Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19
